Experience

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S reopening by Hologic, Inc. of $600 million aggregate principal amount of its 4…

Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of Denali Therapeutics Inc., including shares sold pursuant to the…

Davis Polk advised the joint book-running managers in connection with a $190 million SEC-registered common stock offering of 6,139,515 shares of common stock of Revance Therapeutics,…

Davis Polk advised the sole book-running manager in connection with the $50 million follow-on offering of 1,970,000 shares of common stock of Editas Medicine, Inc. The common…

Davis Polk is advising Aetna on its approximately $77 billion acquisition by CVS Health. The transaction, which is expected to close in the second half of 2018, is subject to approval by…

Davis Polk advised the dealer managers in connection with cash tender offers for (i) any and all of Anthem’s 7.000% notes due 2019 and (ii) up to $836.347 million aggregate principal…

Davis Polk advised the representatives of the several underwriters on an SEC-registered offering by Anthem, Inc. of $5.5 billion in aggregate principal amount of senior notes,…

Davis Polk advised the underwriters of an $805 million SEC-registered offering of 6,440,000 shares of common stock of Alnylam Pharmaceuticals, Inc. Included in the shares are 840,000…

Davis Polk advised Roche Holdings, Inc. as to U.S. law in connection with its cash tender offer for up to €250 million aggregate principal amount of its 6.50% notes due 2021. Headquartered…

Davis Polk advised InflaRx N.V. on its $100 million initial public offering of 6,667,000 of its common shares. In addition, InflaRx has granted the underwriters a 30-day option to purchase…